JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT德国皮肤病学会杂志
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT(英文缩写 J DTSCH DERMATOL GES),ISSN 1610-0379,eISSN 1610-0387,中文译名:德国皮肤病学会杂志 是一本学术期刊。本页汇总该期刊的最新影响因子、分区信息以及最新收录于 PubMed 的文献,帮助您快速了解期刊全貌。
发文量统计区间：2025-09-27 至 2026-09-27，按本站收录文献的发表日期统计。
期刊介绍
历年影响因子趋势
| JCR 数据年份 | 影响因子 | JCR 分区 |
|---|---|---|
| 2021 | 5.231 | Q1 |
| 2022 | 3.600 | Q1 |
| 2023 | 5.500 | Q1 |
| 2024 | 3.800 | Q1 |
| 2025 | 5.000 | Q1 |
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT 最新收录文献
-
2. S1 Guideline: Management of ingrown nails (Unguis incarnatus, Onychocryptosis) and pincer nails (Unguis in turriculo).
PMID:期刊:日期:2026-09-23The newly developed S1 guideline "Management of the Ingrown Nail (Unguis incarnatus, Onychocryptosis) and the Pincer Nail (Unguis in turriculo, Pincer-Nail)" (AWMF Registry Number 013-106) provides, for the first time, structured, practice-oriented recommendations for two common nail disorders that have previously been managed heterogeneously across disciplines. The guideline was developed by a multidisciplinary expert group and is based on the available literature as well as empirical experience in the diagnosis and treatment of ingrown toenails and pincer nails. Its aim is to define diagnostic criteria, preventive measures, and therapeutic approaches. For ingrown nails, the guideline presents definitions, a clinical classification (grades I-III), and corresponding treatment recommendations. Conservative measures, podiatric interventions, and patient-centered prevention are emphasized, while surgical procedures - particularly minimally invasive techniques with partial matrix excision - are recommended for therapy-resistant or severe cases. For pincer nails, definitions, clinical morphology, and potential therapeutic options are described; due to limited data, individualized management is emphasized. The guideline aims to standardize care, reduce treatment variability, and promote a consistent, interdisciplinary approach.
-
4. Evaluation of suspected delayed-type allergy to beta-lactam antibiotics: a 6-year retrospective single center experience.
PMID:期刊:日期:2026-09-21As allergies against beta-lactam antibiotics (BLA) are among the most common drug allergies, diagnostic testing is essential when an allergic reaction is suspected. To investigate the outcomes of allergy testing in patients with delayed-type allergy to BLA. The prevalence of delayed-type allergy to aminopenicillins or other BLA as well as their cross-reactivity, were analyzed by using skin testing (patch, prick, intradermal tests) and drug challenge testing (DCT). Aminopenicillins were the most frequently suspected culprit drugs in the evaluated cohort (n = 487), and delayed-type allergy was confirmed in 29.9% of patients. DCT was positive despite negative skin test results in 6.0% (29/487). Cross reactivity with closely related BLA groups were found in 10% (8/80) of patients. Given that 88.9% (297/334) of patients with previous negative skin test results tolerated the subsequent drug challenge without allergic reaction, the negative predictive value of skin testing appears reliable within a standardized clinical setting. Thorough allergy diagnostic testing prevents re-exposure to culprit drugs and enables the delabeling of patients with suspected drug allergy, thereby avoiding unnecessary treatment restrictions. Allergy testing is therefore an important and effective component of the diagnostic workup following a history of maculopapular exanthema.
-
6. Navigating Treatments in Folliculitis Decalvans: A Comprehensive Systematic Review.
PMID:期刊:日期:2026-09-16Folliculitis decalvans (FD) is a chronic neutrophilic cicatricial alopecia characterized by recurrent scalp inflammation, pustules, tufted hairs, and progressive permanent hair loss. Owing to its relapsing course and the absence of standardized treatment guidelines, therapeutic management remains challenging. This systematic review summarizes available treatment approaches and reported outcomes in FD. A systematic literature search of PubMed, Web of Science, Embase, and Cochrane databases was conducted according to PRISMA guidelines and registered in PROSPERO (CRD42023467796). Studies published between 1999 and December 2024 reporting treatment outcomes in at least one patient with FD were included. Full remission was defined as complete absence of inflammatory activity with stable disease, while partial remission indicated clinical improvement without relevant alopecia progression. Overall, 64 studies comprising 300 patients were included, mainly retrospective studies, case series, and case reports with low levels of evidence. Antibiotic-based therapies, particularly rifampicin-clindamycin combinations, showed favorable initial responses but frequent relapse after discontinuation. Isotretinoin demonstrated comparatively durable responses, with remission rates up to 82%. Biologic and targeted immunomodulatory therapies, including TNF-α inhibitors, apremilast, and various JAK inhibitors, showed promising outcomes in refractory cases. Current evidence supports individualized long-term treatment strategies focused on inflammation control and prevention of irreversible scarring.
-
9. A 1% glycopyrronium bromide cream for topical treatment of severe primary axillary hyperhidrosis in adolescents: safety, local tolerability, systemic exposure and efficacy from an open-label phase II study.
PMID:期刊:日期:2026-09-15Primary axillary hyperhidrosis (PAHH) results from dysregulation of the autonomic nervous system and typically begins during puberty. Treatment options for adolescents remain limited. This open-label phase II study evaluated the safety, local tolerability, systemic exposure, and efficacy of 1% GPB cream over 8 weeks in adolescents with severe PAHH. A total of 42 adolescents (23 male [55%] and 19 female [45%]; aged 12-17 years) applied the cream once daily for the first 4 weeks and thereafter as needed (at least twice weekly but no more than once daily). The primary endpoints assessed adverse drug reactions (ADRs), local tolerability, and systemic glycopyrronium exposure. Changes in sweat production, PAHH severity, and quality of life were assessed in all patients. Two patients experienced mild ADRs (dry eye and increased conjugated bilirubin in one patient each); no serious adverse events occurred. All 40 evaluable patients had a skin reaction score of 0 throughout treatment. Total sweat production decreased significantly from baseline to day 29 (p < 0.001) and day 57 (p < 0.001). Patient-rated hyperhidrosis severity (PRHS) and quality of life, assessed using the Children's Dermatology Life Quality Index (CDLQI), also improved significantly at both time points (all p < 0.001). 1% GPB cream showed favorable safety and tolerability and improved clinical outcomes in adolescents with severe PAHH, consistent with findings in adults.
-
10. Two Blastic Plasmacytoid Dendritic Cell Neoplasms treated with the CD123-targeted agent Tagraxofusp presenting divergent outcomes.
PMID:期刊:日期:2026-09-14该文献暂无摘要。